Europe Multi Cancer Early Detection Market Size & Outlook
Europe multi cancer early detection market, 2018-2030 (US$M)
Related Markets
Europe multi cancer early detection market highlights
- The Europe multi cancer early detection market generated a revenue of USD 312.3 million in 2022.
- The market is expected to grow at a CAGR of 14.2% from 2023 to 2030.
- In terms of segment, gene panel, ldt & others was the largest revenue generating type in 2022.
- Liquid Biopsy is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, France is expected to register the highest CAGR from 2023 to 2030.
Europe data book summary
| Market revenue in 2022 | USD 312.3 million |
| Market revenue in 2030 | USD 901.0 million |
| Growth rate | 14.2% (CAGR from 2022 to 2030) |
| Largest segment | Gene panel, ldt & others |
| Fastest growing segment | Liquid Biopsy |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Liquid Biopsy, Gene Panel, LDT & Others |
| Key market players worldwide | Illumina Inc, Exact Sciences Corp, Foundation Medicine, Guardant Health Inc, Burning Rock Biotech Ltd ADR, Freenome, AnchorDx, GeneCast, Elypta |
Other key industry trends
- In terms of revenue, Europe region accounted for 36.5% of the global multi cancer early detection market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 1,289.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Multi Cancer Early Detection Market Scope
Multi Cancer Early Detection Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe multi cancer early detection market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to multi cancer early detection market will help companies and investors design strategic landscapes.
Gene panel, ldt & others was the largest segment with a revenue share of 99.55% in 2022. Horizon Databook has segmented the Europe multi cancer early detection market based on liquid biopsy, gene panel, ldt & others covering the revenue growth of each sub-segment from 2018 to 2030.
Europe accounts for the largest revenue share of the MCED market due to the presence of developed economies, such as Germany, Spain, the UK, France, and Italy. These countries have advanced infrastructure, which is anticipated to significantly boost clinical research prospects in the region.
Moreover, the market growth can be attributed to a growing biotechnology industry and rising investments in genomic sequencing in countries such as the UK & Germany. Most European countries use liquid biopsy tests as a part of screening for various types of cancers.
This market is expected to grow exponentially during the forecast period owing to increase in number of approvals by regulatory bodies, intense competition between companies to increase market share, government initiatives, and improving reimbursement scenario.
Reasons to subscribe to Europe multi cancer early detection market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe multi cancer early detection market databook
-
Our clientele includes a mix of multi cancer early detection market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe multi cancer early detection market , including forecasts for subscribers. This continent databook contains high-level insights into Europe multi cancer early detection market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe multi cancer early detection market size, by country, 2018-2030 (US$M)
Europe Multi Cancer Early Detection Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
